Tag Archives: CLVS

Thursday’s Midday Movers: Rite Aid Corp (RAD), Clovis Oncology (CLVS), TG Therapeutics (TGTX), Cytosorbents Corp (CTSO), First Majestic Silver (AG)

So far Thursday, September 12, NASDAQ is up 0.38% and the S&P is up 0.83%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Rite Aid Corp (RAD – Research Report), Clovis Oncology (CLVS

The President & CEO of Clovis Oncology (NASDAQ: CLVS) is Buying Shares

Today, the President & CEO of Clovis Oncology (CLVS – Research Report), Patrick Mahaffy, bought shares of CLVS for $279.6K. Following this transaction Patrick Mahaffy’s holding in the company was increased by 5.74% to a total of $5.18 million. In

A Director at Clovis Oncology (NASDAQ: CLVS) is Buying Shares

Today, a Director at Clovis Oncology (CLVS – Research Report), Thorlef Spickschen, bought shares of CLVS for $50.23K. This recent transaction increases Thorlef Spickschen’s holding in the company by 22.79% to a total of $264.7K. In addition to Thorlef Spickschen,

Thursday’s Midday Stock Update: Clovis Oncology (CLVS), Anthera Pharmaceuticals (ANTH), Agenus Inc (AGEN), Calumet Specialty Products (CLMT), NovaBay Pharma (NBY)

So far Thursday, August 8, NASDAQ is up 4.09% and the S&P is up 2.96%. Here are this morning’s most active stocks: Clovis Oncology (CLVS – Research Report), Anthera Pharmaceuticals (ANTH – Research Report), Agenus Inc (AGEN – Research Report),

Clovis Oncology (CLVS) Receives a Buy from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology (CLVS – Research Report), with a price target of $36. The company’s shares closed yesterday at $8.87, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS) and Unum Therapeutics Inc (NASDAQ: UMRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clovis Oncology (CLVS – Research Report) and Unum Therapeutics Inc (UMRX – Research Report) with bullish sentiments. Clovis Oncology (CLVS) In a